Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, the trial will measure improvements in liver histology with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis.
Lead Product(s): GSK4532990
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GSK4532990
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: GSK
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2023
Details:
Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist designed to improve NASH by increasing hepatic fat metabolism and reducing lipotoxicity.
Lead Product(s): Resmetirom
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MGL-3196
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
The results from the study indicated that via both manual and AI assessment, NASH resolution was dose dependent, with a higher proportion of patients receiving semaglutide 0.4mg achieving NASH resolution without fibrosis worsening, compared to patients receiving placebo.
Lead Product(s): Semaglutide
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2021